STAT+: Aurobindo, major generic drug maker, will close a key U.S. production plant

The move comes after Aurobindo was cited in late 2020 by the FDA for a long list of manufacturing violations at its New Jersey facility.

Aurobindo Pharma, which is based in India and is one of the largest global producers of generic medicines, is closing its U.S. manufacturing facility in New Jersey next month, according to a notice filed with the state Department of Labor.

In its filing, the generic drug company disclosed it is terminating operations of its Aurolife Pharma unit in Dayton, N.J., and will eliminate a total of 99 jobs as of April 26. No further details were provided and calls to the facility were not returned. No one at Aurobindo headquarters in Hyderabad, India, could be reached for comment.

Continue to STAT+ to read the full story…